IP-10 based immunological monitoring
AssigneeHvidovre Hospital
InventorsMorten Ruhwald, Pernille Ravn, Jesper Eugen-Olsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunological method and, more particularly, a method for measuring cell-mediated immune reactivity (CMI) in mammals based on the production of IP-10. The invention further discloses an assay and a kit for measuring CMI to an antigen using whole blood or other suitable biological samples. The methods of the present invention are useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications, thus the invention further relates to a method for diagnosing an infection in a mammal.
Claims8
A method for diagnosing an infection caused by Mycobacteria comprising:
- a) incubating a sample comprising T-cells obtained from a human with at least one Mycobacteria specific peptide or protein test-antigen under the proviso that said test-antigen is not PPD,
- b) determining the test-antigen specific cell-mediated immune response by measuring the IP-10 level in said sample,
- c) comparing the determined IP-10 level with a reference-level, and
- d) classifying said human as one that is likely to be infected with at least one Mycobacteria, if the determined IP-10 level is equal to or above the reference level or classifying said human as one that is unlikely to be infected with at least one Mycobacteria, if said determined IP-10 level is below the reference level.
A method for diagnosing an infection caused by Mycobacteria comprising:
- a) incubating a first fraction of a sample comprising T-cells obtained from a human with at least one Mycobacteria specific peptide or protein test-antigen to generate a response sample, under the proviso that said test-antigen is not PPD,
- b) incubating a second fraction of the sample with an inactive solution to generate a nil sample,
- c) determining the IP-10 levels in the two fractions,
- d) determining the test-antigen dependent cell-mediated immune response by subtracting the IP-10 level determined in the nil sample from the IP-10 level determined in the response sample,
- e) comparing the test-antigen dependent cell-mediated immune response or a value derived thereof with a reference-level or a value derived thereof, and
- f) classifying said human as one that is likely to have an infection if said determined test-antigen specific cell-mediated immune response level is equal to or above the reference level or a value derived thereof or classifying said human as one that is unlikely to have an infection if said determined test-antigen specific cell-mediated immune response level is below the reference level or a value derived thereof.
Dependencies are inferred from the claim text.